To evaluate incontinence severity and patient reported outcomes (PROs) of women undergoing concomitant surgical treatment of early stage endometrial cancer and stress urinary incontinence (SUI) compared to women who chose cancer surgery with non-surgical treatment of incontinence, and to women choosing cancer surgery alone. MATERIALS AND METHODS: Secondary analysis of a large multi-center, prospective cohort study conducted across eight US sites. Women with endometrial epithelial neoplasia (EIN) or clinical stage I/II endometrial cancer were screened for SUI at their oncology appointment. Those screening positive for SUI were eligible for enrollment and were offered a referral to a urogynecologist. As clinically appropriate, women were offered SUI surgery to be performed at the time of their cancer surgery. SUI severity was assessed using the Sandvik Severity Index (SSI) at baseline, 6 weeks, and 6-months post-op. PROs were assessed with the Urogenital Distress Inventory, and the Incontinence Impact Questionnaire (IIQ). Scores were compared by group and time using Chi-square, Kruskal-Wallis, and Friedman tests. Multivariable logistic regression with generalized estimating equations was used to examine the relationship between SUI treatment group and absence of incontinence symptoms (score ¼ zero), adjusting for baseline demographic and clinical factors. RESULTS: Of 509 eligible women, 107 (21%) chose concomitant SUI surgery with their cancer surgery, 96 (19%) chose non-surgical SUI treatment with cancer surgery and 306 (60%) chose cancer surgery alone. At 6-months post-operatively, after adjusting for baseline demographic and clinical factors, the odds of no distress (0 UDIStress score) were significantly higher for the concomitant surgery group compared to the non-surgical group (OR¼2.8, p¼0.0001) or compared to the no treatment group (OR¼3.7, p<0.0001) ( Figure  1) . Additionally, the odds of continence (0 SSI score) were significantly higher for the concomitant surgery group compared to the non-surgical group (OR 2.9, p¼0.0008) or compared to the no treatment group (OR¼2.7, p<0.0001). SSI scores of "severe" or "very severe" decreased from 57% to 14% in the concomitant group (p<0.0001) (Figure 2 ). There were no differences between the groups in the IIQ (Figure 3) . CONCLUSION: Patients undergoing concomitant surgery for SUI and endometrial cancer are more likely to report no leakage or bothersome symptoms compared to women choosing non-surgical treatment for SUI or cancer surgery alone. Women with early stage endometrial cancer and EIN commonly have SUI, and concomitant surgical treatment should be considered as a treatment option.
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13 Postoperative narcotic utilization in older women after pelvic organ prolapse surgery OBJECTIVES: To quantify narcotic utilization (total consumption) by older women during the first week after pelvic organ prolapse (POP) surgery. MATERIALS AND METHODS: This is an interim, ancillary analysis of a prospective cohort study assessing changes in cognition in women !60 years undergoing POP surgery on an academic urogynecology service. Exclusion criteria include diagnosis of cognitive impairment, history of stroke or chronic neurologic condition, use of antipsychotic medication, or Modified Mini-Mental State Examination score of less than 84. Baseline sociodemographic, medical history, intraoperative and postoperative variables, and adverse events through 6 weeks postoperatively were abstracted from the electronic medical record (EMR). Women were asked to complete diaries recording daily narcotic use from hospital discharge through postoperative day (POD) #7. To quantify narcotic use, total narcotic consumption was calculated including any narcotic administration inpatient after surgery and home narcotic use after discharge. Narcotic use was standardized to morphine milligram equivalents (MMEs) and analyzed using summary statistics. Chi-squared (Fisher's exact) tests and Student's T (Mann U Whitney) tests were used to analyze categorical and continuous variables. Regression models were created to assess the association between clinical factors and home narcotic use. RESULTS: Analyses were conducted on narcotic use data provided by 85 of 105 enrolled women. Mean age was 71.9AE5.9 years (range 60-88). The majority were white (95.3%, n¼81). 69.4% (n¼59) underwent vaginal surgery and 30.6% (n¼26) underwent laparoscopic/robotic surgery, with concomitant hysterectomy in 59.3% (n¼51). Mean operative time was 2.43AE0.86 hours. 84.9% (n¼73) were discharged the day of surgery. 65.5% (n¼55) received MS Contin (15 mg) prior to the start of the procedure. 32.9% (n¼28) reported no use of home narcotics. Median (IQR) MMEs after surgery was 5.63 (0-13.35) on POD0 and 7.5 (0-15) on POD1. Median MMEs was 0 POD 2-7. The median total MMEs used during the first week after surgery is 28.9 (6.4e65). Most women were prescribed 30 narcotic tablets on discharge. 6 women did not fill narcotic prescription. Regression statistics found there weren't any factors that were significantly associated with home narcotic use. Variables included in multivariable models included frailty exhaustion score (p¼0.16), Beck anxiety inventory score (p¼0.19), general anesthesia (p¼0.09), intraoperative fentanyl (p¼0.13), phenylephrine use (p¼0.08) and intraoperative hydromorphone use (p¼0.06), and estimated blood loss (p¼0.14). In the final model, none of the variables were significantly associated with home narcotic use. CONCLUSION: Narcotic consumption after POP surgery in older women is modest and equates to 4 (1-9) 5 mg oxycodone tablets generally taken within the first 48 hours of surgery.
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14 Catheter burden following urogynecologic surgery 
OBJECTIVES:
The aim of this study is to compare the catheter burden in women using an indwelling Foley catheter (IFC) versus clean intermittent self-catheterization (CISC) for voiding dysfunction following pelvic reconstructive surgery.
